John Rewcastle, PhD

Not a urologist but I study urology: prostate cancer screening, biopsy, treatment & harm reduction. Also dabble in regulatory affairs. Opinions are my own.

[John Rewcastle, PhD @rewcastle_john]

If you’re going to establish a new #prostatecancer treatment do it right from the get go. Not just one RCT but two. https://t.co/k5oVLOeRn2

[John Rewcastle, PhD @rewcastle_john]

@CanesDavid This summarizes SO much…

[𝙳𝚊𝚟𝚒𝚍 𝙲𝚊𝚗𝚎𝚜 @CanesDavid]

American Express: "This call will be monitored and recorded for quality assurance and training purposes."

Me: "Ok, in that case I will also record the call."

American Express: "Ok in that case if you are recording the call, we cannot proceed."

🙄

[Dr. Rodrigo Donalisio @RdonalisioMD]

🚨 LIVE from AUA – @marcojruro is presenting metanalysis of BPH treatment.Congrats to this outstanding urology candidate-soon to be Research Fellow in Cincinnati and future Urology Resident! Proud to support the next generation of innovators. #AUA2026 #Urology #BPH #Endourology

[John Rewcastle, PhD @rewcastle_john]

My 24th AUA: #AUA26 is in the books. Great clinical science, discussions and progress. Can’t wait until next year!

[John Rewcastle, PhD @rewcastle_john]

My favourite slide from #AUA2026 presented by Indy Gill. We need a better solution for localized #prostatecancer

[John Rewcastle, PhD @rewcastle_john]

@docakx In as much as all cats are not dangerous (kittens vs. tigers) not all cancer is lethal (GG1 prostate cancer vs. Stage 4 lung cancer)

[John Rewcastle, PhD @rewcastle_john]

@docakx In as much as all cats are not dangerous (kittens vs. tigers) not all cancer is lethal (GG1 prostate cancer vs. Stage 4 lung cancer)

[John Rewcastle, PhD @rewcastle_john]

Any KM curve showing biopsy results from AS or focal therapy should include, on the same graph a freedom from biopsy KM curve! It’s hard to interpret without knowing the denominator. #eau26 #prostatecancer

[John Rewcastle, PhD @rewcastle_john]

@DongNguyeb @MrJosephNorris @DrSpratticus Regarding point 1: it is not off label. Period.

[John Rewcastle, PhD @rewcastle_john]

@fgomsan PRO = patient reported outcomes: IPSS, IIEF, EPIC-26 and the like. What was this gentleman’s PRO function before and after Tx?

[John Rewcastle, PhD @rewcastle_john]

@jimhumd These options all seem heavy handed in light of ProtecT. There are a few certainties w/ PCa. One is that
favourable intermediate rest disease can absolutely safely be watch for a year. Watch it - change your treatment decision basis being a photograph to a movie!

[John Rewcastle, PhD @rewcastle_john]

Aquablation demonstrated noninferior short-term LUTS relief and similar safety compared to LEP, with superior ejaculation preservation and avoidance of SUI in short-term follow-up. #BPH #Aquablation #menshealth https://t.co/0Ki1g2OlbL

[Dr. Marty Makary @DrMakaryFDA]

FDA is now open to Bayesian statistical approaches. A leap forward!

Bayesian statistics can help:
✅ Clinical trial design
✅ Finding the optimal dose
✅ Extrapolation to children
✅ Leveraging phase 2 results in phase 3

[Garrett D Pohlman, M.D. @gpohlmanmd]

Dr. Inderbir Gill, @USC_Urology discusses how the WATER IV Prostate Cancer trial came about - which compares #Aquablation to Radical Prostatectomy. @PROCEPTRobotics https://t.co/ooflH0eluh

[John Rewcastle, PhD @rewcastle_john]

@DrRishabhOnco I disagree that ProtecT is a low-risk study. A third of the patients were intermediate risk at diagnosis, but it was before MRI. If you diagnosed the ProtecT population today with MRI guided biopsy half would be intermediate-risk.

[John Rewcastle, PhD @rewcastle_john]

@DrRishabhOnco I disagree that ProtecT is a low-risk study. A third of the patients were intermediate risk at diagnosis, but it was before MRI. If you diagnosed the ProtecT population today with MRI guided biopsy half would be intermediate-risk.

[Elena Castro @Ecastromarcos]

Just out in @TheLancet: an overview on current approaches to diagnosis and management of prostate cancer.
https://t.co/AhomCOFkZg

[Jim Hu @jimhumd]

👀 Important work on under appreciation of GG1 cancer in the MRI era by @ShuWangMD @EvanSuzman @nyphospital @UTSWMedCenter @WeillCornell: Trends of upgrading and upstaging of grade group 1 prostate ... : Current Urology https://t.co/Ke9wmHnlGM